摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Benzyl-cis-4-aminocyclohexancarboxylat | 67299-44-9

中文名称
——
中文别名
——
英文名称
Benzyl-cis-4-aminocyclohexancarboxylat
英文别名
benzyl(1s,4s)-4-aminocyclohexane-1-carboxylate
Benzyl-cis-4-aminocyclohexancarboxylat化学式
CAS
67299-44-9
化学式
C14H19NO2
mdl
——
分子量
233.31
InChiKey
VUPFWCRTJAOTKD-BETUJISGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    342.9±35.0 °C(Predicted)
  • 密度:
    1.098±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.25
  • 重原子数:
    17.0
  • 可旋转键数:
    3.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    52.32
  • 氢给体数:
    1.0
  • 氢受体数:
    3.0

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Novel Selective Inhibitors of Neutral Endopeptidase for the Treatment of Female Sexual Arousal Disorder. Synthesis and Activity of Functionalized Glutaramides
    摘要:
    Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.(1)
    DOI:
    10.1021/jm060133g
  • 作为产物:
    参考文献:
    名称:
    [EN] ORGANIC ARSENIC-BASED TYPE II PYRUVATE KINASE INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF
    [FR] INHIBITEUR DE LA PYRUVATE KINASE DE TYPE II À BASE D'ARSENIC ORGANIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
    [ZH] 一类基于有机砷的II型丙酮酸激酶抑制剂及其制备方法和用途
    摘要:
    本发明提供了一种基于有机砷的II型丙酮酸激酶抑制剂及其制备方法和用途。具体地,本发明的PKM2抑制剂为式I化合物、或其药学上可接受的盐、或其立体异构体或互变异构体、水合物或溶剂化物;其中,X1、X2、R1、R2、R3、R4、R5和n如说明书所定义。本发明的化合物对PKM2具有高抑制活性和高特异性,非常适合用于制备通过抑制PKM2通路从而抑制肿瘤的药物。
    公开号:
    WO2021254254A1
  • 作为试剂:
    描述:
    1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentane-1-carboxylic acid 、 Benzyl-cis-4-aminocyclohexancarboxylatBenzyl-cis-4-aminocyclohexancarboxylat 作用下, 以86的产率得到
    参考文献:
    名称:
    Enantiomeric glutaramide diuretic agents
    摘要:
    公开号:
    EP0342850B1
点击查看最新优质反应信息

文献信息

  • VLA-4 inhibitor compounds
    申请人:Daiichi Pharmaceutical Co., LTD.
    公开号:US20030078249A1
    公开(公告)日:2003-04-24
    Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: 1 As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.
    本发明公开了选择性抑制配体与α4β1整合素(VLA-4)结合的化合物及其制备方法。在一个实施例中,本发明的化合物由式I表示: 1 作为VLA-4介导的细胞粘附的选择性抑制剂,本发明的化合物可用于治疗与该粘附相关的疾病,包括但不限于炎症和自身免疫反应、糖尿病、哮喘、屑病、炎症性肠病、移植排斥和肿瘤转移。还公开了包含式I化合物的药物组合物、抑制VLA-4介导的细胞粘附的方法以及治疗与VLA-4介导的细胞粘附相关疾病的方法。
  • Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists
    申请人:DeVita J. Robert
    公开号:US20080076783A1
    公开(公告)日:2008-03-27
    The present invention is directed to certain piperidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
    本发明涉及某些哌啶化合物,其作为神经激肽-1(NK-1)受体拮抗剂和快速激肽,特别是物质P的抑制剂是有用的。本发明还涉及包含这些化合物作为活性成分的制药配方,并且涉及将这些化合物及其配方用于治疗某些疾病,包括呕吐、尿失禁、抑郁症和焦虑症。
  • NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE)
    申请人:Baxter E. Ellen
    公开号:US20070259898A1
    公开(公告)日:2007-11-08
    The present invention is directed to novel 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.
    本发明涉及新颖的2-基-3,4-二氢-吡啶[3,4-d]嘧啶生物,含有它们的制药组合物以及它们在治疗阿尔茨海默病(AD)和相关疾病中的应用。本发明的化合物是β-分泌酶的抑制剂,也称为β-位点剪切酶和BACE,BACE1,Asp2和memapsin2。
  • 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION
    申请人:JONES Clifford
    公开号:US20100063049A1
    公开(公告)日:2010-03-11
    Compounds of formula (I): which possess cell-cycle inhibitory activity are described.
    本文描述了具有细胞周期抑制活性的化合物,其化学式为(I)。
  • 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of β-secretase (BACE)
    申请人:Janssen Pharmaceutica, N.V.
    公开号:US07531545B2
    公开(公告)日:2009-05-12
    The present invention is directed to novel 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.
    本发明涉及新型2-基-3,4-二氢-吡啶[3,4-d]嘧啶生物,包含它们的制药组合物以及它们在治疗阿尔茨海默病(AD)和相关疾病中的应用。本发明的化合物是β-分泌酶的抑制剂,也称为β-位点剪切酶和BACE、BACE1、Asp2和memapsin2。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸